Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07387003 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 300 → 345 participants Primary completion moved earlier from Apr 22, 2027 to Feb 11, 2027 · Completion pushed from Aug 17, 2027 to Sep 23, 2027 · Start date: Mar 20, 2026 to Apr 10, 2026 · 1 morev2 Show 4 more changesShow less
    • Primary completion moved earlier from Apr 22, 2027 to Feb 11, 2027
    • Completion pushed from Aug 17, 2027 to Sep 23, 2027
    • Start date: Mar 20, 2026 to Apr 10, 2026
    • Interventions: GZR101-80 (Drug), Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) (Drug) to GZR101-80 (Drug), GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) (Drug)
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.
Trial Details
NCT Number NCT07387003
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes (T2DM)
Enrollment 345 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov